» Articles » PMID: 22652868

Heterogeneity of Cancer-initiating Cells Within Glioblastoma

Overview
Specialty Biology
Date 2012 Jun 2
PMID 22652868
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant gliomas, particularly glioblastoma multiforme (GBM), account for the majority of brain tumors. Their incidence is increasing world wide and they are incurable. Although a transient response to therapy is observed, tumor recurrence is inevitable and occurs within tissue that has received cytotoxic therapy. This suggests that a subpopulation of resistant cells is responsible for tumor regrowth. The treatment of GBMs represents a daunting challenge to clinicians due principally to the lack of effective therapeutic options. One explanation for this is the marked cellular and genetic heterogeneity within and across these types of tumors. Unravelling the cellular composition of gliomas and describing cell lineage relationships are essential for therapeutic breakthroughs. The recent proposal that a small percentage of cells with stem cells characteristics are responsible for tumor initiation and growth has sparked an interest in applying approaches used to study somatic stem cells toward an understanding of the cellular elements responsible for cancer progression and recurrence. To outline the relevance of these findings is the purpose of this review.

Citing Articles

ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma.

Gravina G, Colapietro A, Mancini A, Rossetti A, Martellucci S, Ventura L Cancers (Basel). 2022; 14(2).

PMID: 35053455 PMC: 8773508. DOI: 10.3390/cancers14020289.


Matrix Hyaluronic Acid and Hypoxia Influence a CD133 Subset of Patient-Derived Glioblastoma Cells.

Chen J, Leary S, Barnhouse V, Sarkaria J, Harley B Tissue Eng Part A. 2021; 28(7-8):330-340.

PMID: 34435883 PMC: 9057908. DOI: 10.1089/ten.TEA.2021.0117.


Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model.

Chen J, Lumibao J, Leary S, Sarkaria J, Steelman A, Gaskins H J Neuroinflammation. 2020; 17(1):346.

PMID: 33208156 PMC: 7677841. DOI: 10.1186/s12974-020-02026-6.


Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme.

Jnaidi R, Almeida A, Goncalves L Pharmaceutics. 2020; 12(9).

PMID: 32927610 PMC: 7558650. DOI: 10.3390/pharmaceutics12090860.


Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness.

Su Y, Lin J, Shih J, Chuang H, Fong I, Yeh C Cells. 2020; 9(8).

PMID: 32784466 PMC: 7463574. DOI: 10.3390/cells9081859.